Exclusive Summary

• Core patents have completely expired globally, presenting zero IP barriers and allowing distributors to seamlessly proceed with localized registration and commercial launch.
• Targeting over 60 million global patients with schizophrenia and bipolar disorder, this injection is a highly frequent, essential medication for controlling acute agitation in emergencies.
• As a second-generation atypical antipsychotic, it offers the distinct first-line clinical advantage of rapid onset within 15-30 minutes, alongside minimal extrapyramidal and metabolic side effects.
• The lyophilized powder injection has high technological and sterile manufacturing barriers, leading to significantly less market competition compared to oral forms and helping partners build a differentiated portfolio.
• Supported by China's premium supply chain capabilities and full CTD registration dossiers, its immense cost advantage effectively boosts clients' outbidding success rate in public hospital procurement tenders.